[go: up one dir, main page]

AR008630A1 - Indol-3-glioxilamidas n-sustituidas con efecto antiasmatico, antialergico e inmunosupresor/inmunomodulador, procedimientos para su preparacion, suutilizacion farmaceutica y las composiciones farmaceuticas que las contienen. - Google Patents

Indol-3-glioxilamidas n-sustituidas con efecto antiasmatico, antialergico e inmunosupresor/inmunomodulador, procedimientos para su preparacion, suutilizacion farmaceutica y las composiciones farmaceuticas que las contienen.

Info

Publication number
AR008630A1
AR008630A1 ARP970104064A ARP970104064A AR008630A1 AR 008630 A1 AR008630 A1 AR 008630A1 AR P970104064 A ARP970104064 A AR P970104064A AR P970104064 A ARP970104064 A AR P970104064A AR 008630 A1 AR008630 A1 AR 008630A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical
procedures
substituted
glioxilamidas
asmatic
Prior art date
Application number
ARP970104064A
Other languages
English (en)
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of AR008630A1 publication Critical patent/AR008630A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Nuevas indol-3-glioxilamidas n-sustituidas, de formula (i): donde la definicion de los sustituyentes consta en la memoria, procedimientos para suelaboracion y su utilizacion farmacéutica. Los compuestos presentan efectos antialérgicos e inmunosupresores/inmunomoduladores.
ARP970104064A 1996-09-06 1997-09-05 Indol-3-glioxilamidas n-sustituidas con efecto antiasmatico, antialergico e inmunosupresor/inmunomodulador, procedimientos para su preparacion, suutilizacion farmaceutica y las composiciones farmaceuticas que las contienen. AR008630A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19636150A DE19636150A1 (de) 1996-09-06 1996-09-06 N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung

Publications (1)

Publication Number Publication Date
AR008630A1 true AR008630A1 (es) 2000-02-09

Family

ID=7804772

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104064A AR008630A1 (es) 1996-09-06 1997-09-05 Indol-3-glioxilamidas n-sustituidas con efecto antiasmatico, antialergico e inmunosupresor/inmunomodulador, procedimientos para su preparacion, suutilizacion farmaceutica y las composiciones farmaceuticas que las contienen.

Country Status (26)

Country Link
US (4) US6008231A (es)
EP (1) EP0931063B3 (es)
JP (1) JP3296437B2 (es)
KR (1) KR100516321B1 (es)
CN (3) CN100376554C (es)
AR (1) AR008630A1 (es)
AT (1) ATE342889T1 (es)
AU (1) AU726521B2 (es)
BR (1) BR9712808B1 (es)
CA (1) CA2215013C (es)
CZ (1) CZ302301B6 (es)
DE (2) DE19636150A1 (es)
DK (1) DK0931063T5 (es)
ES (1) ES2276433T7 (es)
HU (1) HU227797B1 (es)
IL (1) IL127798A (es)
NO (2) NO314725B3 (es)
NZ (1) NZ334476A (es)
PT (1) PT931063E (es)
RU (1) RU2237661C2 (es)
SK (1) SK285618B6 (es)
TR (1) TR199900469T2 (es)
TW (1) TW550256B (es)
UA (1) UA60312C2 (es)
WO (1) WO1998009946A1 (es)
ZA (1) ZA977475B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
KR100584650B1 (ko) * 1998-03-31 2006-05-30 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산
DE19946301A1 (de) 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
CZ302588B6 (cs) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
JP3842043B2 (ja) 1998-04-28 2006-11-08 エルビオン アクチエンゲゼルシャフト 新規ヒドロキシインドール、ホスホジエステラーゼ４のインヒビタとしてのその使用及びその製法
DE19917504A1 (de) * 1999-04-17 2000-10-19 Dresden Arzneimittel Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
EP1671651B1 (en) 1999-08-21 2009-11-11 Nycomed GmbH Synergistic combination of pumafentrine and salmeterol
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
CA2460347A1 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamideindoles for treating cancer
RU2337906C2 (ru) * 2001-12-03 2008-11-10 Уайт Ингибиторы цитозольной фосфолипазы а2
TWI323658B (en) * 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
JP2006500336A (ja) * 2002-07-26 2006-01-05 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 糖尿病合併症の処置に使用するための置換インドールアルカン酸誘導体及びそれを含む製剤。
NZ537947A (en) * 2002-08-01 2006-11-30 Elbion Ag Method for producing highly pure hydroxy indolyl glyoxylic acid amides
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318610A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
DE10334040A1 (de) * 2003-07-25 2005-03-10 Zentaris Gmbh Neue N-substituierte Indolyl-3-glyoxylsäureamide, deren Verwendung als Arzneimittel und Verfahren zu deren Herstellung
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
JP2008519036A (ja) * 2004-11-08 2008-06-05 バクスター・インターナショナル・インコーポレイテッド チューブリン阻害化合物のナノ粒子組成物
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP2006247963A (ja) * 2005-03-09 2006-09-21 Oji Paper Co Ltd インクジェット記録用シート
EP1865949B1 (en) * 2005-03-11 2012-11-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP1896707A2 (en) 2005-04-29 2008-03-12 Tendix Development, LLC Radial impulse engine, pump, and compressor systems, and associated methods of operation
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
BRPI0713768A2 (pt) 2006-07-05 2012-10-30 Nycomed Gmbh combinação de inibidores de reductase de hmg-coa com inibidores de fosfodiesterase 4 para o tratamento de doenças pulmonares inflamatórias
WO2008019357A2 (en) * 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
JP2010509237A (ja) * 2006-11-02 2010-03-25 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
US20080241274A1 (en) * 2006-11-28 2008-10-02 Ziopharm Oncology, Inc. Indibulin therapy
MY205872A (en) 2009-04-29 2024-11-18 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising omega-3 fatty acids
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
KR101774223B1 (ko) 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
AU2012313971B2 (en) 2011-09-27 2016-09-29 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN109000634B (zh) * 2018-06-04 2022-06-03 上海智蕙林医疗科技有限公司 一种导航对象行进路线的提醒方法和系统

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797258A (en) * 1955-04-11 1958-06-25 Upjohn Co 3-substituted indoles
GB944443A (es) * 1959-09-25 1900-01-01
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
GB1089071A (en) * 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
US3686213A (en) * 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
SU457698A1 (ru) * 1972-10-20 1975-01-25 Всесоюзный научно-исследовательский химико-фармацевтический институт им. Серго Орджоникидзе Способ получени производных индолил-2-уксусной кислоты
FR2689888B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
ZA952693B (en) * 1994-04-01 1996-09-30 Lilly Co Eli 1H-indole-3-Glyoxylamide sPLA2 inhibitors
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect

Also Published As

Publication number Publication date
CZ302301B6 (cs) 2011-02-09
US6344467B1 (en) 2002-02-05
EP0931063A1 (de) 1999-07-28
SK285618B6 (sk) 2007-05-03
BR9712808B1 (pt) 2009-05-05
HK1021641A1 (zh) 2000-06-23
IL127798A (en) 2003-07-31
TW550256B (en) 2003-09-01
CN101219985B (zh) 2011-04-27
CZ61699A3 (cs) 1999-06-16
WO1998009946A1 (de) 1998-03-12
HUP9903741A2 (hu) 2000-04-28
AU4015897A (en) 1998-03-26
CN100488948C (zh) 2009-05-20
US20030207892A1 (en) 2003-11-06
KR20000068495A (ko) 2000-11-25
HK1064379A1 (zh) 2005-01-28
CN100376554C (zh) 2008-03-26
SK27199A3 (en) 1999-08-06
NO991071D0 (no) 1999-03-04
DK0931063T3 (da) 2007-02-19
TR199900469T2 (xx) 1999-05-21
EP0931063B1 (de) 2006-10-18
AU726521C (en) 1998-03-26
KR100516321B1 (ko) 2005-09-23
NZ334476A (en) 2000-05-26
HK1123280A1 (en) 2009-06-12
ES2276433T7 (es) 2009-11-05
CN1227542A (zh) 1999-09-01
HU227797B1 (en) 2012-03-28
DE19636150A1 (de) 1998-03-12
CN101219985A (zh) 2008-07-16
RU2237661C2 (ru) 2004-10-10
ES2276433T3 (es) 2007-06-16
PT931063E (pt) 2007-02-28
UA60312C2 (uk) 2003-10-15
CA2215013A1 (en) 1998-03-06
NO20030481D0 (no) 2003-01-30
CA2215013C (en) 2002-03-05
ATE342889T1 (de) 2006-11-15
NO314725B1 (no) 2003-05-12
US6008231A (en) 1999-12-28
JP3296437B2 (ja) 2002-07-02
CN1496980A (zh) 2004-05-19
DK0931063T5 (da) 2010-01-11
IL127798A0 (en) 1999-10-28
ZA977475B (en) 1998-02-19
NO991071L (no) 1999-03-04
EP0931063B3 (de) 2009-04-08
NO314725B3 (no) 2009-03-09
JP2000505098A (ja) 2000-04-25
BR9712808A (pt) 1999-11-23
DE59712752D1 (de) 2006-11-30
AU726521B2 (en) 2000-11-09
NO20030481L (no) 1999-03-04
HUP9903741A3 (en) 2001-01-29
US20020161025A1 (en) 2002-10-31
US6919344B2 (en) 2005-07-19

Similar Documents

Publication Publication Date Title
AR008630A1 (es) Indol-3-glioxilamidas n-sustituidas con efecto antiasmatico, antialergico e inmunosupresor/inmunomodulador, procedimientos para su preparacion, suutilizacion farmaceutica y las composiciones farmaceuticas que las contienen.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9704777A (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y composiciones que los contienen.
MX9700557A (es) Dihidrobenzofuranos.
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
ES2122043T3 (es) Nuevos derivados sustituidos del pirazol, procedimientos para su preparacion y su empleo como herbicidas.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
YU60996A (sh) Inhibitor protein kinaze c, njegove faramceutske formulacije i postupak za dobijanje
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2084944T3 (es) Amidas terapeuticas.
MX9202289A (es) Nuevos derivados de tiopiranopirrol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR030185A1 (es) Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas
DE69429003D1 (de) Flavonoid und biflavonoid,derivate, pharmazeutische zusammensetzung und ihre anxiolytische wirkung
MX9201356A (es) Derivados de piperidina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
ES2174298T3 (es) Derivados de aminotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
MX9300628A (es) Nuevos derivados de taxano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
CY1106376T1 (el) Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration